Patents by Inventor Patrick Hagner

Patrick Hagner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230364230
    Abstract: The present application relates to methods of treating, managing and/or preventing cancer, comprising administering (a) a protein that comprises (i) an antigen-binding site that binds an antigen on a natural killer (NK) cell, and (ii) an antigen-binding site that binds an antigen on a cell of said cancer; and (b) iberdomide (CC-220), avadomide (CC-122), lenalidomide, pomalidomide, or CC-92480. The present application also relates to methods of treating, managing and/or preventing cancer, comprising administering (a) a protein that comprises (i) an antigen-binding site that binds NKG2D, and (ii) an antigen-binding site that binds an antigen on a cell of said cancer, and (ii) an antigen-binding site that binds an antigen on a cell of said cancer; and (b) iberdomide (CC-220), avadomide (CC-122), lenalidomide, pomalidomide, or CC-92480.
    Type: Application
    Filed: September 10, 2021
    Publication date: November 16, 2023
    Inventors: William Pierceall, Patrick Hagner, Hsiling Chiu, Safiyyah N. Ziyad, Anjan Guha Thakurta, Mark Orr
  • Publication number: 20230023070
    Abstract: Provided herein are methods of treating and/or managing cancer, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof. Additionally, provided herein are methods of treating and/or managing cancer, which comprise administering to a patient Compound A, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, in combination with a second agent selected from the group consisting of an anti-CD20 antibody, an HDAC inhibitor, a proteasome inhibitor, an anti-CD38 antibody, an anti-SLAMF7 antibody, a nuclear export inhibitor, a BCL-2 inhibitor, and an immune checkpoint inhibitor. Also provided herein are combination therapies for treating and/or managing cancer, which further comprise dexamethasone as a third agent.
    Type: Application
    Filed: December 1, 2020
    Publication date: January 26, 2023
    Inventors: Chad Bjorklund, Hsiling Chiu, Patrick Hagner, Jian Kang, Anjan Thakurta
  • Publication number: 20220003749
    Abstract: Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.
    Type: Application
    Filed: April 1, 2021
    Publication date: January 6, 2022
    Applicant: CELGENE CORPORATION
    Inventors: Matthew William Burnell TROTTER, Patrick HAGNER, Courtney G. HAVENS, Rajesh CHOPRA, Anita GANDHI, Anke KLIPPEL, Maria Yinglin WANG, Mike BREIDER, Suzana Sturlini COUTO, Yan REN, Paul HOLLENBACH, Kyle MACBETH
  • Patent number: 10996215
    Abstract: Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: May 4, 2021
    Assignee: CELGENE CORPORATION
    Inventors: Matthew William Burnell Trotter, Patrick Hagner, Courtney G. Havens, Rajesh Chopra, Anita Gandhi, Anke Klippel, Maria Yinglin Wang, Mike Breider, Suzana Sturlini Couto, Yan Ren, Paul Hollenbach, Kyle Macbeth
  • Publication number: 20210102257
    Abstract: In one aspect, provided herein are methods for predicting the responsiveness of DLBCL patients to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classfiers that correlate with responsiveness to one of these drugs. In another aspect, provided herein are methods for treating a DLBCL patient determined to be responsive to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classifiers (or output thereof) that correlate with responsiveness to one of these drugs.
    Type: Application
    Filed: May 18, 2020
    Publication date: April 8, 2021
    Applicant: Celgene Corporation
    Inventors: Matthew William Burnell Trotter, Alberto Risueno Perez, Michael Pourdehnad, Anita Gandhi, Patrick Hagner
  • Patent number: 10689708
    Abstract: In one aspect, provided herein are methods for predicting the responsiveness of DLBCL patients to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classifiers that correlate with responsiveness to one of these drugs. In another aspect, provided herein are methods for treating a DLBCL patient determined to be responsive to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classifiers (or output thereof) that correlate with responsiveness to one of these drugs.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: June 23, 2020
    Assignee: CELGENE CORPORATION
    Inventors: Matthew William Burnell Trotter, Alberto Risueno Perez, Michael Pourdehnad, Anita Gandhi, Patrick Hagner
  • Publication number: 20190004033
    Abstract: Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.
    Type: Application
    Filed: April 5, 2018
    Publication date: January 3, 2019
    Inventors: Matthew William Burnell TROTTER, Patrick HAGNER, Courtney G. HAVENS, Rajesh CHOPRA, Anita GANDHI, Anke KLIPPEL, Maria Yinglin WANG, Mike BREIDER, Suzana Sturlini COUTO, Yan REN, Paul HOLLENBACH, Kyle MACBETH
  • Patent number: 10159675
    Abstract: Provided herein are methods of treating, preventing and/or managing cancer, including lymphoma, which comprise administering to a patient 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cyclic therapy regimen.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: December 25, 2018
    Assignee: Celgene Corporation
    Inventors: Patrick Hagner, Anita Gandhi, Michael Pourdehnad
  • Publication number: 20180231561
    Abstract: A method of identifying a subject having a solid tumor who is likely to be responsive to a treatment compound, comprising: administering the treatment compound to a subject having the solid tumor; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject, and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker.
    Type: Application
    Filed: August 11, 2016
    Publication date: August 16, 2018
    Inventors: Anita GANDHI, Patrick HAGNER, Rajesh CHOPRA, Anke KLIPPEL
  • Publication number: 20170242014
    Abstract: A method of identifying a subject having a solid tumor who is likely to be responsive to a treatment compound, comprising: administering the treatment compound to a subject having the solid tumor; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject, and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker.
    Type: Application
    Filed: December 5, 2014
    Publication date: August 24, 2017
    Inventors: Patrick HAGNER, Anita GANDHI, Rajesh CHOPRA, Anke KLIPPEL
  • Publication number: 20170157103
    Abstract: Provided herein are methods of treating, preventing and/or managing diffuse large B-cell lymphoma (DLBCL), which comprise administering to a patient 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof.
    Type: Application
    Filed: November 30, 2016
    Publication date: June 8, 2017
    Inventors: Anjan Thakurta, Patrick Hagner, Anita Gandhi
  • Publication number: 20170157123
    Abstract: Provided herein are methods of treating, preventing and/or managing cancer, including lymphoma, which comprise administering to a patient 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof in a cyclic therapy regimen.
    Type: Application
    Filed: December 1, 2016
    Publication date: June 8, 2017
    Inventors: Patrick Hagner, Anita Gandhi, Michael Pourdehnad
  • Publication number: 20170088901
    Abstract: In one aspect, provided herein are methods for predicting the responsiveness of DLBCL patients to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classfiers that correlate with responsiveness to one of these drugs. In another aspect, provided herein are methods for treating a DLBCL patient determined to be responsive to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classifiers (or output thereof) that correlate with responsiveness to one of these drugs.
    Type: Application
    Filed: September 22, 2016
    Publication date: March 30, 2017
    Inventors: Matthew William Burnell Trotter, Alberto Risueno-Perez, Michael Pourdehnad, Anita Gandhi, Patrick Hagner
  • Publication number: 20170038387
    Abstract: A method of identifying a subject having chronic lymphocytic leukemia (CLL) who is likely to be responsive to a treatment compound, comprising obtaining a first sample and a second sample from the subject having CLL; administering 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione (Compound A) to the first sample and administering lenalidomide to the second sample; determining the level of a biomarker in the first sample and determining the level of the biomarker in the second sample; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the first sample is different from the level of the biomarker in the second sample.
    Type: Application
    Filed: August 3, 2016
    Publication date: February 9, 2017
    Inventors: Anita Gandhi, Patrick Hagner, Anke Klippel, Michael Pourdehnad, Matthew William Burnell Trotter, Ming Lei
  • Publication number: 20160313300
    Abstract: Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.
    Type: Application
    Filed: December 5, 2014
    Publication date: October 27, 2016
    Inventors: Matthew William Burnell Trotter, Patrick Hagner, Courtney G. Havens, Rajesh Chopra, Anita Gandhi, Anke Klippel, Maria Yinglin Wang, Mike Breider, Suzana Sturlini Couto, Yan Ren, Paul Hollenbach, Kyle MacBeth